Home / Semaglutide / Wegovy dosage
Wegovy dosage chart
FDA-approved Wegovy is semaglutide, approved for weight management in adults. Every dose below is from its label.
Short answer: start at 0.25 mg once a week for 4 weeks, then step up no faster than every 4 weeks. Maintenance is 2.4 mg once weekly (1.7 mg if 2.4 mg is not tolerated); adults may go up to 7.2 mg. The maximum is 7.2 mg once weekly (after at least 4 weeks on 2.4 mg).
Dose by week
| Step | Weeks | Weekly dose |
|---|---|---|
| 1 | 1-4 | 0.25 mg (starting dose) |
| 2 | 5-8 | 0.5 mg |
| 3 | 9-12 | 1 mg |
| 4 | 13-16 | 1.7 mg |
| 5 | 17 onward | 2.4 mg |
Fastest schedule the label allows. Each step is a minimum, not a deadline.
Maintenance is 2.4 mg (or 1.7 mg). Adults may go up to 7.2 mg after at least 4 weeks on 2.4 mg (Wegovy HD). If a step is not tolerated, the label allows delaying escalation by 4 weeks.
Doses are set by your prescriber. Side effects such as nausea are most common right after a step up: see semaglutide side effects.
Other label charts: Zepbound · Mounjaro · Ozempic
Questions
- What is the starting dose of Wegovy?
- 0.25 mg once weekly for 4 weeks. The label treats it as a starting dose to begin treatment, not as the dose you stay on.
- How long do you stay on each Wegovy dose?
- At least 4 weeks before stepping up. Your prescriber can keep you on a dose longer if side effects are a problem.
- What is the maximum dose of Wegovy?
- 7.2 mg once weekly (after at least 4 weeks on 2.4 mg). Maintenance: 2.4 mg once weekly (1.7 mg if 2.4 mg is not tolerated); adults may go up to 7.2 mg.
- Do I need to count units for Wegovy?
- Not with the branded pen, which delivers the dose for you. Units on an insulin syringe only matter when a dose is drawn from a vial; the semaglutide calculator converts mg to units for a given vial strength.
Sources
- Wegovy (semaglutide) US prescribing information, Novo Nordisk
- FDA approves higher-dose semaglutide under the national priority voucher program (Mar 2026)
- Wilding et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM 2021
Last checked 2026-11-16. How we pick and check sources: methodology.